AP
MYGN icon

AHL Partners’s Myriad Genetics MYGN Stock Holding History

AHL Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.18M Sell
34,298
-45,606
-57% -$1.54M 0.02% 846
2017
Q3 		$2.89M Buy
79,904
+29,753
+59% +$849K 0.05% 552
2017
Q2 		$1.29M Sell
50,151
-28,760
-36% -$611K 0.03% 712
2017
Q1 		$1.51M Buy
78,911
+14,818
+23% +$263K 0.03% 687
2016
Q4 		$1.07M Buy
64,093
+29,888
+87% +$541K 0.03% 654
2016
Q3 		$704K Buy
34,205
+18,366
+116% +$466K 0.03% 698
2016
Q2 		$485K Buy
15,839
+7,798
+97% +$271K 0.03% 615
2016
Q1 		$301K Sell
8,041
-52,541
-87% -$1.98M 0.02% 671
2015
Q4 		$2.62M Buy
60,582
+50,117
+479% +$2.12M 0.2% 182
2015
Q3 		$392K Sell
10,465
-141,097
-93% -$5.01M 0.06% 471
2015
Q2 		$5.15M Sell
151,562
-1,384
-0.9% -$47.1K 0.21% 165
2015
Q1 		$5.41M Buy
152,946
+81,593
+114% +$2.92M 0.22% 141
2014
Q4 		$2.43M Buy
71,353
+60,742
+572% +$2.16M 0.13% 367
2014
Q3 		$409K Buy
+10,611
New +$396K 0.03% 530

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AHL Partners's MYGN Position: Q4 2017 in Review

AHL Partners reduced its Myriad Genetics (MYGN) stake by 57% in Q4 2017, selling an estimated $1.54M and leaving 34,298 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #846.

AHL Partners first reported a position in MYGN in Q3 2014 and has held it in 14 quarters since. The position peaked at $5.41M in Q1 2015. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • AHL Partners held 34,298 shares of Myriad Genetics worth $1.18M as of Q4 2017.
  • AHL Partners sold 45,606 Myriad Genetics shares in Q4 2017, an estimated $1.54M.
  • Myriad Genetics made up 0.02% of AHL Partners's portfolio in Q4 2017, its #846 holding.
  • AHL Partners first reported a position in Myriad Genetics in Q3 2014 and has held it in 14 quarters since.
  • AHL Partners's Myriad Genetics position peaked at $5.41M in Q1 2015.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.